Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study.
about
Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Safety and tolerability of ine ...... s and subcutaneous dose study.
@en
Safety and tolerability of ine ...... s and subcutaneous dose study.
@nl
type
label
Safety and tolerability of ine ...... s and subcutaneous dose study.
@en
Safety and tolerability of ine ...... s and subcutaneous dose study.
@nl
prefLabel
Safety and tolerability of ine ...... s and subcutaneous dose study.
@en
Safety and tolerability of ine ...... s and subcutaneous dose study.
@nl
P2093
P2860
P356
P1476
Safety and tolerability of ine ...... us and subcutaneous dose study
@en
P2093
Andrzej Potemkowski
Armando Flor
Eliezer Katz
Gabriela Klodowska-Duda
Gerard Barron
Jacob Wesley
Kaushik Patra
Maciej Maciejowski
Mark A Agius
P2860
P304
P356
10.1177/1352458517740641
P577
2017-11-16T00:00:00Z